COPHARM12 made agreement with two reputable journals and offer manuscript publication of the willing authors in special issue with relatively fast publication rate. The journals are:

1. Special Issue in the Iraqi Journal of Pharmaceutical Sciences (IJPS), SCOPUS – indexed Q2 CiteScore 2.6 . Journal website: https://bijps.uobaghdad.edu.iq/index.php /bijps
2. Selected high-quality manuscripts may be invited for publication in special issues of affiliated journals, including Scopus- or Clarivate-indexed journals. Journals-specific guidelines will be provided after acceptance.

• The submission of abstracts should be through the conference website after registering in the Indico Link  https://events.uobaghdad.edu.iq/register
• The authors should select one of the thematic areas of COPHARM12.
• There will be two types of conference participations: Podium presentation (10-15 minutes) or poster presentation.
• Abstracts will be reviewed by the Conference Scientific Committee to determine its quality, eligibility, and the type of participation (podium or poster).
• Accepted submissions should have the conference logo on the first slide of the presentation and on the top of the hard copy of the poster.
• Presenters (submitted as live presentation) should email their slides as soft copy of the presentation ( PowerPoint format) to the Scientific Committee  before 10^thof October  via the following link Email Scientific Committee

General Instructions for Authors – Manuscript Submission

1-Eligibility and Originality 

• Published manuscripts can be submitted for participation in conference activities ;specifically in  posters section
• -Manuscripts  , to be presented on conference podium ,  must report original, unpublished research and must be relevant to one of the declared  conference scientific  tracks
• -Simultaneous submission to other conferences or journals is strictly prohibited unless clearly disclosed at the time of submission.
• -The submissions must be free from plagiarism, data fabrication, falsification, or inappropriate image manipulation.

2-Manuscript Type and Length

• Authors should submit full-length original research articles.
• Word count: 4,000–8,000 words (excluding references)
• Required manuscript sections:
• Title
• Authors’ Names and Affiliations
• Abstract (200–300 words)
• Keywords (4–6)
• Introduction
• Materials and Methods
• Results
• Discussion
• Conclusion
• Acknowledgments (if applicable)
• Funding Statement
• Conflict of Interest Statement
• References
• Tables and Figures

3-Language and Style

• Manuscripts must be written in clear, professional English (British or American English; consistency required).
• Authors are responsible for language editing and proofreading before submission.
• Manuscripts with poor language quality may be returned for revision or desk-rejected.

4- Formatting Guidelines

• File format: Microsoft Word (.docx)
• Font: Times New Roman, 12 pt
• Line spacing: Single or 1.5
• Paper size: A4
• Margins: 2.5 cm on all sides
• Figures and Tables
• Must be embedded in the text at appropriate locations
• High resolution and clearly readable
• Numbered consecutively and provided with descriptive captions
• Images must not be manipulated beyond acceptable brightness/contrast adjustments
• Previously published figures require written permission and proper citation

References

• Use Vancouver style
• References must be numbered consecutively in order of first appearance in the text
• Title Page
• A separate title page must be submitted containing:
• Full names of all authors
• Institutional affiliations
• Corresponding author clearly identified
• Email address and ORCID ID (if available)

5. 5. Ethical Requirements

• Authors must declare that:
• The manuscript is original (except for posters)  and free from plagiarism or misconduct
• All authors have approved the final version
• All ethical standards have been followed
• Human and Animal Studies
• Studies involving humans or animals must include:
• Name of the ethics committee
• Approval number/code
• Date of approval
• Human studies must comply with the Declaration of Helsinki
• Animal studies must follow international ethical guidelines (e.g., ARRIVE or institutional standards)
• Informed consent must be stated where applicable

6. 6. Plagiarism and Similarity Check

• All manuscripts will be screened using plagiarism detection software.
• The acceptable similarity index must not exceed 15–20%, excluding references.
• Self-plagiarism is not permitted.
• Manuscripts exceeding the acceptable limit will be rejected without review.

7. Authorship and Contributions

• All listed authors must have made significant scientific contributions to the work.
• An author contribution statement is required or strongly recommended.
• Changes in authorship (addition, removal, or order) after submission are not allowed without written consent from all authors.

8. Funding and Conflict of Interest

• All sources of financial support or sponsorship must be disclosed.

If no funding was received, authors should state: “This research received no specific                     

         grant from any funding agency.”

• Authors must declare any financial or non-financial conflicts of interest.

If none exist, include: “The authors declare no conflict of interest.”

9. Data Availability and Transparency

• Authors must retain original data and provide it upon request.
• A data availability statement is encouraged, indicating whether data are publicly available, restricted, or available upon reasonable request.

10. Supplementary Materials

• Supplementary files (additional data, figures, or protocols) may be submitted.
• Supplementary materials will be reviewed but may not appear in printed proceedings.

11. Submission Process

• Manuscripts must be submitted through one of the following methods:
• Via the conference website submission portal (Indico system):
  https://conf.copharm.uobaghdad.edu.iq
• Or by email to the Scientific Committee (refer to the website for the official email address)
• Cover Letter
• Each submission must include a cover letter stating:
• The scientific significance of the work(and novelty for submitted articles for podium presentation or for publishing in conference related journals )
• Relevance to the conference themes
• Disclosure of any conflicts of interest
• Deadline
• Full manuscript submission deadline: 2^nd October 2026
  (Deadlines may be updated on the conference website; abstract deadlines for presentations may differ.)

12. Peer Review Process

• All submissions will undergo peer review by the Scientific Committee.
• The review process may be single-blind or double-blind (as determined by the conference).
• Submissions may be presented as posters based on Scientific committee decision.
• Authors may be requested to revise manuscripts in response to reviewers’ comments within a specified timeframe.
• Editorial decisions are final.

13. Acceptance, Registration, and Presentation

• Acceptance of a manuscript is conditional upon conference registration.
• At least one author must attend and present the paper.
• Failure to present may result in exclusion from the conference proceedings.

14. Publication Opportunity

Selected high-quality manuscripts may be invited for publication in special issues of affiliated journals, including Scopus- or Clarivate-indexed journals, besides the Iraqi Journal of Pharmaceutical Science (Scopus Q2).Journal-specific guidelines will be provided after acceptance.

15. Copyright and Disclaimer

• Upon acceptance, authors agree to transfer publication rights to the conference organizers.
• Authors retain the right to use their work for academic and educational purposes with proper citation.
• The conference organizers are not responsible for the accuracy of data or opinions expressed in submitted manuscripts.

16. Author Checklist (Before Submission)

• Manuscript follows formatting guidelines
• Abstract within word limit
• Ethics approval included (if applicable)
• Plagiarism check completed
• Conflict of interest declared
• Funding statement included
• References in Vancouver style
• Figures and tables properly labeled
• Cover letter attached